ethinyl estradiol

English name ethinylestradiol

also known as ethinyloestradiol · EE20 · 28-day Levonorgestrel Oral Contraceptive · EE · EE2 · Minidril · Norelgesetromin

Small molecule

Developed for: polycystic ovary syndrome · dysmenorrhea · anovulation · acne · premenstrual dysphoric disorder · infertility disorder · menstrual disorder · premenstrual tension
+40 more
· adenomyosis · depressive disorder · endometrial polyp · endometriosis · hemometra · major depressive disorder · migraine disorder · ovarian endometriosis · pelvis syndrome · premature menopause · primary dysmenorrhea · primary ovarian failure · systemic lupus erythematosus · uterine disorder · amenorrhea · anemia · anorexia nervosa · binge eating disorder · bone remodeling disease · breast cancer · chronic pain syndrome · COVID-19 · cystic fibrosis · endometrial cancer · functional hypothalamic amenorrhea · hidradenitis suppurativa · multiple sclerosis · osteoporosis · ovarian disorder · postpartum depression · pregnancy disorder · sexual disorder · temporomandibular joint disorder · endometrial disorder · female infertility · headache disorder · myocardial ischemia · ovarian cyst · ovarian dysfunction · uterine anomalies
Investigated by: Bayer · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Pfizer · Boehringer Ingelheim · Novo Nordisk A/S
+180 more
· AstraZeneca · Bristol-Myers Squibb · Nobelpharma · Wyeth is now a wholly owned subsidiary of Pfizer · Duramed Research · Janssen Research & Development, LLC · Eli Lilly and Company · GlaxoSmithKline · Population Council · Agile Therapeutics · Massachusetts General Hospital · AbbVie · Laboratorios Andromaco S.A. · Parexel · University of Colorado, Denver · Warner Chilcott · Amgen · Bio-innova Co., Ltd · Canadian Institutes of Health Research (CIHR) · Celerion · Conselho Nacional de Desenvolvimento Científico e Tecnológico · FHI 360 · Janssen Pharmaceutica N.V., Belgium · Mahidol University · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · Novartis Pharmaceuticals · Oregon Health and Science University · Penn State University · Purdue University · Society of Family Planning · Teva Branded Pharmaceutical Products R&D, Inc. · United States Agency for International Development (USAID) · University of Palermo · University of Pennsylvania · University of Roma La Sapienza · University of Saskatchewan · University of Virginia · Vertex Pharmaceuticals Incorporated · ViiV Healthcare · Achillion, a wholly owned subsidiary of Alexion · Aegerion Pharmaceuticals, Inc. · Ain Shams Maternity Hospital · Alexion Pharmaceuticals, Inc. · Altimmune, Inc. · Anuja Dokras · Aquinox Pharmaceuticals (Canada) Inc. · Assembly Biosciences · Astellas Pharma Global Development, Inc. · Astellas Pharma Inc · Atea Pharmaceuticals, Inc. · Basilea Pharmaceutica International Ltd · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · Bial - Portela C S.A. · Biogen · Biolab Sanus Farmaceutica · Blueprint Medicines Corporation · Boston Children's Hospital · Bristol Myers Squibb Company (BMS) · CMN "20 de Noviembre" · CONRAD · Centers for Disease Control and Prevention · Chemo Research · Children's Mercy Hospital Kansas City · Chongqing Medical University · Chulalongkorn University · Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia · Concert Pharmaceuticals · Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. · Covance · Deciphera Pharmaceuticals, LLC · Eastern Virginia Medical School · Ege University · Enanta Pharmaceuticals, Inc · Erasmus Medical Center · all 186 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Evra	—	2002-08-22	europa.eu ↗
Approved	US (FDA)	ESTINYL	—	1943-06-25	fda.gov ↗

Trials 279 · started per year

today

US approved 1943

EU approved 2002

194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT07568509	May 2026 → Apr 2027 expected	hypopituitarism, neurohypophyseal diabetes insipidus	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 0	NCT03905941	Aug 2021 → Nov 2024	polycystic ovary syndrome	University of Virginia	Withdrawn	No outcome recorded
Phase 0	NCT04423068	Dec 2020 → Apr 2022	pregnancy disorder	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
Phase 0	NCT03037944	Mar 2016 → Dec 2017	adenomyosis	Ain Shams Maternity Hospital	Unknown	No outcome recorded
Phase 0	NCT02036879	Feb 2014 → Aug 2018	cystic fibrosis	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1121 trials
Phase 1	NCT07710729	Jul 2026 → Apr 2027 expected	obesity disorder	Novo Nordisk A/S	Not yet recruiting	No outcome recorded
Phase 1	NCT07340190	Jun 2026 → Mar 2028 expected	cancer	Novartis Pharmaceuticals	Recruiting	No outcome recorded
Phase 1	NCT07539090	Jun → Aug 2026 overdue	—	Deciphera Pharmaceuticals, LLC	Recruiting	No outcome recorded
Phase 1	NCT07523711	Apr → Nov 2026 expected	obesity disorder	Amgen	Active not recruiting	No outcome recorded
Phase 1	NCT07525791	Apr 2026 → Apr 2027 expected	obesity disorder	Novo Nordisk A/S	Recruiting	No outcome recorded
Phase 1	NCT07502417	Mar → Jul 2026 overdue	—	AbbVie	Active not recruiting	No outcome recorded
Phase 1	NCT07414784	Feb → Jul 2026 overdue	—	AbbVie	Active not recruiting	No outcome recorded
Phase 1	NCT07388511	Feb → Apr 2026	—	Blueprint Medicines Corporation	Completed	No outcome recorded
Phase 1	NCT07272889	Dec 2025 → Feb 2026	—	Atea Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT07235774	Nov 2025 → Mar 2026	—	Servier	Completed	No outcome recorded
Show all 121 trials opens the full record — a long page
Phase 231 trials
Phase 2	NCT07010146	Oct 2025 → Dec 2029 expected	bone remodeling disease, functional hypothalamic amenorrhea	University of Virginia	Recruiting	No outcome recorded
Phase 2	NCT07083635	Jul 2025 → Sep 2026 expected	hemometra, menstrual disorder	Chulalongkorn University	Recruiting	No outcome recorded
Phase 2	NCT05098574	Feb 2023 → Apr 2024	bipolar disorder, premenstrual dysphoric disorder	St. Joseph's Healthcare Hamilton	Completed	No outcome recorded
Phase 2	NCT05360550	Jul 2022 → Jan 2023	—	Lupin Research Inc	Completed	No outcome recorded
Phase 2	NCT04278755	Sep 2020 → May 2022	binge eating disorder, bulimia nervosa	University of North Carolina, Chapel Hill	Terminated	No outcome recorded
Phase 2	NCT02550977	Sep 2015 → Jul 2016	—	Bayer	Completed	No outcome recorded
Phase 2	NCT01968135	Oct 2013 → Nov 2014	uterine disorder	University of Colorado, Denver	Completed	No outcome recorded
Phase 2	NCT01388491	Oct 2011 → Sep 2012	vascular hemostatic disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01310647	Jun 2011 → Dec 2012	ovarian disorder	La Fe Health Research Institute	Completed	No outcome recorded
Phase 2	NCT01204190	Sep 2010 → Jul 2011	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00896571	Jul 2009 → May 2011	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00915915	Jun 2009 → Apr 2010	anovulation	Bayer	Completed	No outcome recorded
Phase 2	NCT00933179	Jun 2009 → Sep 2010	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00924560	Jun 2009 → Aug 2012	—	Duramed Research	Completed	No outcome recorded
Phase 2	NCT00873483	Apr 2009 → Mar 2010	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00722800	Oct 2008 → Dec 2011	hidradenitis suppurativa	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 2	NCT00729404	Aug 2008 → Feb 2009	anovulation	Bayer	Terminated	No outcome recorded
Phase 2	NCT01250210	Sep 2007 → Feb 2008	anovulation	Agile Therapeutics	Completed	No outcome recorded
Phase 2	NCT00471991	Apr → Dec 2007	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00394771	Oct 2006 → Mar 2008	—	Duramed Research	Completed	No outcome recorded
Phase 2	NCT00338052	Jun 2006 → May 2007	—	Warner Chilcott	Completed	No outcome recorded
Phase 2	NCT00318799	Apr 2006 → May 2007	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00196313	May 2005 → Oct 2008	dysmenorrhea	Duramed Research	Completed	No outcome recorded
Phase 2	NCT00089414	Jul 2004 → Jun 2010	depressive disorder, premenstrual dysphoric disorder	National Institute of Mental Health (NIMH)	Terminated	No outcome recorded
Phase 2	NCT00673686	May 2004 → Feb 2005	—	Bayer	Completed	No outcome recorded
Phase 2	NCT00344383	Nov 2003 → Jul 2004	hemometra	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded
Phase 2	NCT00213096	Mar 2003 → Feb 2004	—	Population Council	Completed	No outcome recorded
Phase 2	NCT00254189	Dec 2002 → Oct 2004	anovulation	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 2	NCT00151801	May 2002 → Dec 2008	multiple sclerosis	S. Andrea Hospital	Unknown	No outcome recorded
Phase 2	NCT00033358	Feb 2002 → Oct 2007	endometrial cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00320567	? → Apr 2004	osteoporosis	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT00511797	Jul 2007 → Jan 2009	dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 2/3	NCT00461305	Feb 2007 → Jan 2009	dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 2/3	NCT00955058	Feb 2007	polycystic ovary syndrome	Shahid Beheshti University	Unknown	No outcome recorded
Phase 2/3	NCT00310791	Apr 2004 → Oct 2009	anorexia nervosa	Boston Children's Hospital	Completed	No outcome recorded
Phase 358 trials
Phase 3	NCT07714616	May 2027 → May 2029 expected	—	Eurofarma Laboratorios S.A.	Not yet recruiting	No outcome recorded
Phase 3	NCT05139121	Oct 2021 → Jan 2025	—	Mylan Technologies Inc.	Completed	No outcome recorded
Phase 3	NCT03945513	Dec 2019 → Jun 2023	—	Insud Pharma	Completed	No outcome recorded
Phase 3	NCT04007874	Sep 2019 → Dec 2024	migraine disorder	Leiden University Medical Center	Unknown	No outcome recorded
Phase 3	NCT03843736	Feb 2019 → Jun 2020	polycystic ovary syndrome	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 3	NCT03229057	Jan 2018 → Jan 2024	polycystic ovary syndrome	Anuja Dokras	Completed	No outcome recorded
Phase 3	NCT02922348	Mar 2016 → Dec 2018	primary ovarian failure	University of Pennsylvania	Withdrawn	No outcome recorded
Phase 3	NCT02617537	Jan 2016 → Sep 2017	dysmenorrhea	Bayer	Withdrawn	No outcome recorded
Phase 3	NCT02362711	Feb 2015 → Jan 2017	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT02158572	Aug 2014 → Nov 2016	—	Agile Therapeutics	Completed	No outcome recorded
Phase 3	NCT01892904	Jul 2013 → Jan 2015	dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 3	NCT03359057	Feb → Jul 2013	—	Galeno Desenvolvimento de Pesquisas Clínicas	Completed	No outcome recorded
Phase 3	NCT01697111	Oct 2012 → Mar 2014	endometriosis	Bayer	Completed	No outcome recorded
Phase 3	NCT02021097	Feb 2012 → Feb 2015	—	Regenex Pharmaceutical, China	Unknown	No outcome recorded
Phase 3	NCT01246791	Nov 2010 → May 2011	—	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT01181479	Aug 2010 → Dec 2011	—	Agile Therapeutics	Completed	No outcome recorded
Phase 3	NCT01129102	May 2010 → Apr 2011	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT01044498	Dec 2009 → Feb 2012	rheumatoid arthritis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00996580	Oct 2009 → Sep 2011	—	Teva Women's Health	Completed	No outcome recorded
Phase 3	NCT00910637	May 2009 → Dec 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00902746	May 2009 → Feb 2012	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00984789	May 2009 → Sep 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00914693	Apr 2009 → Sep 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00824187	Jan 2009 → Jan 2011	premenstrual dysphoric disorder	Bayer	Completed	No outcome recorded
Phase 3	NCT00818519	Dec 2008 → May 2010	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00746096	Sep 2008 → Sep 2009	primary dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00569244	Dec 2007 → Dec 2009	primary dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 3	NCT00567164	Oct 2007 → Nov 2009	anovulation	Bayer	Completed	No outcome recorded
Phase 3	NCT00455156	Dec 2006 → Jan 2009	—	Premier Research	Completed	No outcome recorded
Phase 3	NCT00391807	Nov 2006 → Aug 2008	—	Warner Chilcott	Completed	No outcome recorded
Phase 3	NCT00263341	Dec 2005 → Aug 2014	—	Population Council	Completed	No outcome recorded
Phase 3	NCT00266032	Dec 2005 → Oct 2008	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00195559	Sep 2005 → Dec 2007	premenstrual dysphoric disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00128934	Aug 2005 → Dec 2007	premenstrual tension	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00117260	Jul 2005 → Jul 2007	—	Duramed Research	Withdrawn	No outcome recorded
Phase 3	NCT00193726	Jul 2005 → Mar 2012	breast cancer	Sudeep Gupta	Terminated	No outcome recorded
Phase 3	NCT00161681	Jul 2005 → Aug 2006	premenstrual tension	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00212277	Feb 2005 → Sep 2006	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00196365	Jan 2005 → Jul 2007	dysmenorrhea	Duramed Research	Completed	No outcome recorded
Phase 3	NCT00212342	Dec 2004 → Jan 2006	dysmenorrhea	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT00185354	Nov 2004 → Apr 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00229996	Jul 2004 → ?	endometriosis, pelvis syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00280657	Mar 2004 → May 2005	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00624130	Mar 2004 → Jun 2005	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00185484	Mar 2004 → Jan 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00220324	Feb 2004 → Nov 2005	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00932321	Jan → Nov 2004	—	Warner Chilcott	Completed	No outcome recorded
Phase 3	NCT00185419	Nov 2003 → Mar 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00196352	May 2003 → Nov 2006	—	Duramed Research	Completed	No outcome recorded
Phase 3	NCT00245921	Feb 2003 → Oct 2005	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00656981	Jan 2003 → Jun 2004	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00651469	Jan 2003 → Jul 2004	acne	Bayer	Completed	No outcome recorded
Phase 3	NCT00367276	Dec 2002 → May 2004	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00236769	Nov 1997 → Oct 1999	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00236782	Oct 1997 → Mar 1999	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00000420	Jun 1997 → Aug 2003	systemic lupus erythematosus	NYU Langone Health	Completed	No outcome recorded
Phase 3	NCT00236795	Jan 1997 → Mar 1999	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00248963	? → Oct 2004	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded

Phase 433 trials
Phase 4	NCT06334315	Oct 2024 → May 2028 expected	—	Yale University	Recruiting	No outcome recorded
Phase 4	NCT06067256	Jul → Dec 2023	—	Italfarmaco	Unknown	No outcome recorded
Phase 4	NCT06324851	Jan → Aug 2023	endometrial polyp	University of Palermo	Completed	No outcome recorded
Phase 4	NCT06316206	Jan → Aug 2023	endometrial polyp	University of Palermo	Completed	No outcome recorded
Phase 4	NCT05002738	Sep 2021 → Nov 2022	—	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT04828824	Jun 2021 → Nov 2025	—	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT03077555	Jan 2017 → Feb 2018	anovulation	Mahidol University	Completed	No outcome recorded
Phase 4	NCT02710708	May 2016 → Jul 2018	—	Bayer	Completed	No outcome recorded
Phase 4	NCT02531321	Aug 2015 → Nov 2016	HIV infectious disease	University of Southern California	Terminated	No outcome recorded
Phase 4	NCT02352090	Apr 2015 → Dec 2018	—	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT02367833	Jan 2015 → Dec 2017	bone disorder	Penn State University	Completed	No outcome recorded
Phase 4	NCT02367846	Jan 2015 → Dec 2028 expected	bone development disease	Penn State University	Active not recruiting	No outcome recorded
Phase 4	NCT02210702	Jul 2014 → Jan 2015	postpartum depression	The Jones Institute	Unknown	No outcome recorded
Phase 4	NCT02237131	Apr 2014 → Apr 2015	dysmenorrhea, ovarian endometriosis, pelvis syndrome	University of Athens	Unknown	No outcome recorded
Phase 4	NCT02027337	Dec 2013 → Mar 2015	menstrual disorder, polycystic ovary syndrome	Tyumen State Medical Academy	Unknown	No outcome recorded
Phase 4	NCT01941134	Apr 2013 → Dec 2017	—	Johns Hopkins University	Withdrawn	No outcome recorded
Phase 4	NCT01757249	Jan → Nov 2013	infertility disorder	University of Oxford	Terminated	No outcome recorded
Phase 4	NCT01608698	Jun 2012 → Jan 2016	—	Mahidol University	Unknown	No outcome recorded
Phase 4	NCT01490190	Dec 2011 → Dec 2012	—	Organon and Co	Completed	No outcome recorded
Phase 4	NCT01448291	Oct 2011 → Oct 2012	bacterial vaginosis	Eastern Virginia Medical School	Unknown	No outcome recorded
Phase 4	NCT01360996	Aug 2011 → Feb 2015	polycystic ovary syndrome	Woman's	Completed	No outcome recorded
Phase 4	NCT01219101	Mar 2011 → Nov 2012	infertility disorder	Royan Institute	Completed	No outcome recorded
Phase 4	NCT02342093	Jan 2011 → Jul 2013	hypertensive disorder	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT01103518	Dec 2009 → Nov 2010	amenorrhea, dysmenorrhea	Fundação Educacional Serra dos Órgãos	Unknown	No outcome recorded
Phase 4	NCT01170390	Sep 2009 → Mar 2011	—	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT00826839	Jan 2009 → Sep 2010	infertility disorder	Weill Medical College of Cornell University	Withdrawn	No outcome recorded
Phase 4	NCT01174524	Jan → Nov 2008	—	Hospital Geral de Fortaleza	Completed	No outcome recorded
Phase 4	NCT00570440	Aug 2007 → Oct 2010	—	FHI 360	Completed	No outcome recorded
Phase 4	NCT00204451	Jul 2005 → Jun 2006	—	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00261482	Jul 2003 → Dec 2004	—	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 4	NCT00307632	Feb 2003 → Dec 2004	—	Janssen-Cilag Farmaceutica Ltda.	Completed	No outcome recorded
Phase 4	NCT00653016	Oct 2002 → Aug 2003	—	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 4	NCT00732693	Feb 2002 → Nov 2006	primary ovarian failure	University of Edinburgh	Completed	No outcome recorded

Phase not applicable27 trials
—	NCT07361263	Jan 2026 → Feb 2027 expected	diabetes insipidus	University Hospital, Basel, Switzerland	Recruiting	No outcome recorded
—	NCT07127458	Aug 2025 → Mar 2026	polycystic ovary syndrome	Ege University	Completed	No outcome recorded
—	NCT05233956	Oct 2023 → Dec 2026 expected	anemia	FHI 360	Active not recruiting	No outcome recorded
—	NCT04778514	Dec 2022 → Sep 2023	HIV infectious disease	Population Council	Completed	No outcome recorded
—	NCT05212389	Dec 2021 → Aug 2024	disease by molecular mechanism, major depressive disorder	Rigshospitalet, Denmark	Unknown	No outcome recorded
—	NCT02556411	Jun → Dec 2021	adenomyosis, chronic pain syndrome	University of Cagliari	Unknown	No outcome recorded
—	NCT04831151	Mar 2021 → Mar 2023	polycystic ovary syndrome	Inonu University	Unknown	No outcome recorded
—	NCT04539626	Oct 2020 → Apr 2023	COVID-19	CMN "20 de Noviembre"	Unknown	No outcome recorded
—	NCT04451746	Jun 2020 → Feb 2026	chronic venous insufficiency	Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia	Completed	No outcome recorded
—	NCT06560944	Jan 2020 → Jan 2024	—	University of Lincoln	Completed	No outcome recorded
—	NCT03043924	Sep 2017 → Apr 2022	polycystic ovary syndrome	University Hospital, Lille	Completed	No outcome recorded
—	NCT03230825	Sep 2017 → Sep 2018	—	Meir Medical Center	Unknown	No outcome recorded
—	NCT02865187	Feb 2017 → Mar 2020	polycystic ovary syndrome, sexual disorder	Wright State University	Completed	No outcome recorded
—	NCT02757469	May 2016 → May 2020	premature menopause	Navy General Hospital, Beijing	Unknown	No outcome recorded
—	NCT02529683	Apr 2014 → Aug 2015	—	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT01546454	Feb → Jun 2012	coronary artery disorder	Oregon Health and Science University	Completed	No outcome recorded
—	NCT01573377	Feb 2012 → Feb 2013	polycystic ovary syndrome	Chongqing Medical University	Completed	No outcome recorded
—	NCT01459445	Feb → Jun 2011	polycystic ovary syndrome	Iuliu Hatieganu University of Medicine and Pharmacy	Unknown	No outcome recorded
—	NCT01414530	Apr 2010 → Jun 2014	premature menopause	Samsung Medical Center	Unknown	No outcome recorded
—	NCT00999479	Oct 2009 → Oct 2011	ovarian endometriosis	University of Oklahoma	Withdrawn	No outcome recorded
—	NCT00633360	Feb 2008 → May 2011	depressive disorder, premenstrual tension	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00442689	Jul 2006 → Nov 2012	metabolic syndrome X, polycystic ovary syndrome	Northwestern University	Completed	No outcome recorded
—	NCT00237042	Oct 2005 → Jun 2010	temporomandibular joint disorder	University of Washington	Completed	No outcome recorded
—	NCT01372293	Jan 2005 → Jan 2008	polycystic ovary syndrome	Federal University of Rio Grande do Sul	Completed	No outcome recorded
—	NCT00350480	Apr 2003 → Jun 2005	menstrual disorder, uterine disorder	Kaiser Permanente	Completed	No outcome recorded
—	NCT00204438	Feb → Dec 2002	—	University of Saskatchewan	Completed	No outcome recorded
—	NCT00006133	Jun 2000 → ?	systemic lupus erythematosus	National Center for Research Resources (NCRR)	Completed	No outcome recorded

Also used as a comparator or background therapy in 109 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02689843 Comparator	Feb → Nov 2018	polycystic ovary syndrome	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 110 trials
Phase 1	NCT07269327 Background	Nov 2025 → Mar 2026	infertility disorder	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 1	NCT05282940 Comparator	Feb → Mar 2022	—	Laboratorios Andromaco S.A.	Completed	No outcome recorded
Phase 1	NCT04713904 Comparator	Jan 2021	—	Laboratorios Andromaco S.A.	Completed	No outcome recorded
Phase 1	NCT04272008 Comparator	Mar 2020 → Jun 2021	—	TherapeuticsMD	Completed	No outcome recorded
Phase 1	NCT04290390 Comparator	Feb 2020 → Jan 2021	—	TherapeuticsMD	Completed	No outcome recorded
Phase 1	NCT03755037 Comparator	Jan 2017 → Apr 2018	female infertility	Nesreen Abdel Fattah Abdullah Shehata	Completed	No outcome recorded
Phase 1	NCT01258660 Background	Dec 2006 → Jan 2008	—	Bayer	Completed	No outcome recorded
Phase 1	NCT00357604 Comparator	Jul → Nov 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00647933 Background	Jun → Dec 2000	infertility disorder	Organon and Co	Completed	No outcome recorded
Phase 1	NCT02182791 Comparator	Apr 1998 → Apr 1999	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/23 trials
Phase 1/2	NCT03881904 Comparator	Jun 2017 → Jul 2019	female infertility	Ain Shams University	Unknown	No outcome recorded
Phase 1/2	NCT02957630 Comparator	Sep 2016 → Oct 2017	—	Estetra	Completed	No outcome recorded
Phase 1/2	NCT00517556 Comparator	Aug 2007 → Mar 2011	dysmenorrhea	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 29 trials
Phase 2	NCT07288190 Background	May 2026 → May 2028 expected	HIV infectious disease, pregnancy disorder	HIV Prevention Trials Network	Not yet recruiting	No outcome recorded
Phase 2	NCT06852365 Comparator	Jun 2025 → Apr 2028 expected	metabolic syndrome X, polycystic ovary syndrome	University of Pennsylvania	Recruiting	No outcome recorded
Phase 2	NCT03091595 Comparator	Feb 2017 → Jun 2018	—	Estetra	Completed	No outcome recorded
Phase 2	NCT02729545 Comparator	Apr 2016 → Mar 2018	polycystic ovary syndrome	Beijing Hospital of Integrated Traditional Chinese and Western Medicine	Completed	No outcome recorded
Phase 2	NCT03172533 Comparator	Mar 2016 → Jan 2019	anorexia nervosa	University of Erlangen-Nürnberg Medical School	Terminated	No outcome recorded
Phase 2	NCT01709318 Comparator	Dec 2012 → Oct 2013	—	Organon and Co	Completed	No outcome recorded
Phase 2	NCT01252186 Comparator	Nov 2010 → Dec 2011	vascular hemostatic disease	Teva Women's Health	Completed	No outcome recorded
Phase 2	NCT00439972 Comparator	Feb 2007 → Dec 2011	—	University of Washington	Unknown	No outcome recorded
Phase 2	NCT00185224 Comparator	Mar 2005 → Mar 2006	—	Bayer	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT02669238 Comparator	May 2018 → Oct 2019	endometriosis	Centre Hospitalier Universitaire de la Réunion	Terminated	No outcome recorded
Phase 2/3	NCT03357640 Comparator	May 2017 → May 2018	ovarian cyst	Benha University	Unknown	No outcome recorded
Phase 2/3	NCT04256200 Comparator	Feb 2017 → Nov 2021	endometriosis	American University of Beirut Medical Center	Unknown	No outcome recorded
Phase 2/3	NCT02599077 Comparator	Nov 2015 → Nov 2017	endometriosis	Fundación Santa Fe de Bogota	Suspended	No outcome recorded
Phase 336 trials
Phase 3	NCT07536763 Comparator	Jul 2026 → Jun 2029 expected	—	Dr. Hang Wun Raymond Li	Not yet recruiting	No outcome recorded
Phase 3	NCT03074045 Comparator	Mar 2017 → Sep 2018	—	Bayer	Completed	No outcome recorded
Phase 3	NCT02616146 Comparator	Dec 2015 → Oct 2016	—	Organon and Co	Terminated	No outcome recorded
Phase 3	NCT02562053 Comparator	Oct 2015 → Sep 2017	premenstrual tension	Cairo University	Unknown	No outcome recorded
Phase 3	NCT02488538 Comparator	Jul 2015 → Jul 2017	premenstrual tension	Cairo University	Unknown	No outcome recorded
Phase 3	NCT03106454 Comparator	Aug 2014 → Jan 2024	anovulation	University of Southern California	Completed	No outcome recorded
Phase 3	NCT02089620 Comparator	May 2014 → Jun 2015	premenstrual tension	Beni-Suef University	Completed	No outcome recorded
Phase 3	NCT01902264 Background	Aug 2013 → Feb 2015	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01656434 Comparator	Nov 2012 → Feb 2014	—	Organon and Co	Terminated	No outcome recorded
Phase 3	NCT01254292 Comparator	Jan 2011 → Jan 2013	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01253824 Comparator	Jan → Jul 2011	—	Nobelpharma	Completed	No outcome recorded
Phase 3	NCT01590849 Comparator	Jan 2011 → May 2012	—	Instituto do Coracao	Unknown	No outcome recorded
Phase 3	NCT01257984 Background	Dec 2010 → Aug 2012	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01076582 Comparator	Apr 2010 → Oct 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00920985 Comparator	Jun 2009 → Aug 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00946192 Comparator	May 2009 → Feb 2020	functional hypothalamic amenorrhea	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00722761 Comparator	Apr 2009 → Apr 2012	acne	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00909857 Comparator	Apr 2009 → Nov 2010	primary dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 3	NCT00764881 Comparator	Jan 2009 → Jul 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00778609 Comparator	Dec 2008 → Dec 2010	headache disorder, pelvis syndrome	Bayer	Completed	No outcome recorded
Phase 3	NCT00819312 Comparator	Dec 2008 → Jan 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01581814 Comparator	Oct 2008 → Jul 2011	polycystic ovary syndrome	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 3	NCT00754065 Comparator	Sep 2008 → May 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00468481 Comparator	Apr 2007 → Aug 2008	neural tube defect	Bayer	Completed	No outcome recorded
Phase 3	NCT00948402 Comparator	Dec 2006	polycystic ovary syndrome	Federico II University	Completed	No outcome recorded
Phase 3	NCT00511355 Comparator	Oct 2006 → Jan 2008	—	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00511433 Comparator	Oct 2006 → Jan 2008	—	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00511342 Comparator	Sep 2006 → Jun 2009	—	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00413062 Comparator	Jun 2006 → Aug 2008	—	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00511199 Comparator	May 2006 → Apr 2008	—	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00283816 Comparator	Jan 2006 → Jan 2008	polycystic ovary syndrome	University of Rochester	Completed	No outcome recorded
Phase 3	NCT00185367 Comparator	Mar 2005 → Sep 2006	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00302666 Comparator	Jun 2003 → Feb 2005	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00029159 Comparator	Nov 1992 → Jan 2007	Turner syndrome	Thomas Jefferson University	Completed	No outcome recorded
Phase 3	NCT00191113 Background	Feb 1989 → Dec 2007	Turner syndrome	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00301587 Background	? → Dec 2004	neural tube defect	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Withdrawn	No outcome recorded

Phase 427 trials
Phase 4	NCT07544966 Comparator	Jun 2026 → Apr 2028 expected	major depressive disorder	University of North Carolina, Chapel Hill	Not yet recruiting	No outcome recorded
Phase 4	NCT06083935 Background	Nov 2023 → Aug 2024	polycystic ovary syndrome	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT03236740 Comparator	Aug 2017 → Mar 2018	polycystic ovary syndrome	S.C.B. Medical College and Hospital	Completed	No outcome recorded
Phase 4	NCT02866786 Comparator	Aug 2016 → Apr 2017	polycystic ovary syndrome	S.C.B. Medical College and Hospital	Completed	No outcome recorded
Phase 4	NCT03531437 Comparator	Mar 2016 → Jan 2018	thrombophilia	Mahidol University	Terminated	No outcome recorded
Phase 4	NCT02577601 Comparator	Sep 2015 → Jun 2017	—	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT03124524 Comparator	Jan 2015 → Sep 2016	primary dysmenorrhea	Adana Numune Training and Research Hospital	Completed	No outcome recorded
Phase 4	NCT01963403 Comparator	Dec 2013 → Jul 2015	uterine disorder	University of California, Davis	Terminated	No outcome recorded
Phase 4	NCT01638767 Comparator	Jul 2012 → Jul 2014	infertility disorder	Clinique Ovo	Terminated	No outcome recorded
Phase 4	NCT01588873 Comparator	Apr 2012 → Dec 2018	—	University of Oulu	Unknown	No outcome recorded
Phase 4	NCT01569113 Comparator	Mar → Aug 2012	—	HRA Pharma	Completed	No outcome recorded
Phase 4	NCT01501448 Comparator	Jan → May 2012	infertility disorder	IVI Madrid	Completed	No outcome recorded
Phase 4	NCT01475513 Comparator	Nov 2011 → May 2014	menstrual disorder	Virginia Commonwealth University	Completed	No outcome recorded
Phase 4	NCT01384331 Comparator	Jul 2011 → Dec 2012	menstrual disorder	Family Planning Association New South Wales	Unknown	No outcome recorded
Phase 4	NCT01482338 Background	Jun 2011 → Feb 2012	premenstrual tension	Chulalongkorn University	Completed	No outcome recorded
Phase 4	NCT01388582 Comparator	Apr → Aug 2011	—	University of Campinas, Brazil	Completed	No outcome recorded
Phase 4	NCT00829114 Comparator	Mar 2009 → Apr 2011	AIDS	FHI 360	Completed	No outcome recorded
Phase 4	NCT01466673 Comparator	Dec 2008 → Mar 2010	acne	Janssen-Cilag Ltd.,Thailand	Completed	No outcome recorded
Phase 4	NCT00927095 Comparator	Jul 2008 → Jul 2014	premenstrual dysphoric disorder	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 4	NCT01056042 Comparator	Jun 2007 → Apr 2011	endometriosis	Prince of Songkla University	Completed	No outcome recorded
Phase 4	NCT00827632 Comparator	Jul 2006 → Dec 2008	ovarian dysfunction	Columbia University	Completed	No outcome recorded
Phase 4	NCT00662454 Comparator	Jan → May 2006	—	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT00205504 Comparator	Jun 2005 → Jun 2009	cardiovascular disorder, metabolic syndrome X, obesity disorder	Virginia Commonwealth University	Completed	No outcome recorded
Phase 4	NCT00640224 Comparator	Mar 2005 → Jul 2015	polycystic ovary syndrome	Silva Arslanian	Completed	No outcome recorded
Phase 4	NCT01044056 Comparator	Mar → Jun 2004	—	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00651846 Background	Jun 2003 → Feb 2005	—	Bayer	Completed	No outcome recorded
Phase 4	NCT01511822 Comparator	—	polycystic ovary syndrome	AGUNCO Obstetrics and Gynecology Centre	Completed	No outcome recorded

Phase not applicable19 trials
—	NCT07242131 Comparator	Dec 2025 → Jun 2026 overdue	polycystic ovary syndrome	Ege University	Recruiting	No outcome recorded
—	NCT07229209 Comparator	Feb → May 2025	uterine anomalies, uterine disorder	Benha University	Completed	No outcome recorded
—	NCT07513480 Background	Aug 2024 → Nov 2025	polycystic ovary syndrome	Mst.Sumyara Khatun	Completed	No outcome recorded
—	NCT06396221 Comparator	May → Sep 2024	anovulation	Chulalongkorn University	Completed	No outcome recorded
—	NCT06396208 Comparator	May → Oct 2024	anovulation	Chulalongkorn University	Completed	No outcome recorded
—	NCT03890042 Comparator	Mar 2019 → Jul 2020	adenomyosis	Assiut University	Completed	No outcome recorded
—	NCT05594186 Comparator	Mar 2019 → Oct 2022	—	Saudi German Hospital - Madinah	Completed	No outcome recorded
—	NCT02460445 Background	Jan 2015 → Jun 2020	cardiovascular-kidney-metabolic syndrome	Manuel Luque Ramírez	Completed	No outcome recorded
—	NCT02400801 Comparator	Jun 2013 → Dec 2017	endometriosis, female infertility	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
—	NCT02002260 Comparator	Feb 2013 → Jun 2019	endometrial disorder, ovarian dysfunction	Women and Infants Hospital of Rhode Island	Unknown	No outcome recorded
—	NCT02257671 Comparator	Feb 2012 → Aug 2015	—	Karolinska University Hospital	Unknown	No outcome recorded
—	NCT01519401 Comparator	Feb 2010 → Jul 2011	polycystic ovary syndrome	Catholic University of the Sacred Heart	Completed	No outcome recorded
—	NCT01087879 Comparator	Oct 2007 → Jan 2011	—	University of Oulu	Completed	No outcome recorded
—	NCT00972439 Comparator	Aug 2007 → Nov 2008	—	University of Southern California	Completed	No outcome recorded
—	NCT00612508 Comparator	May 2007 → May 2008	—	Oregon Health and Science University	Completed	No outcome recorded
—	NCT01465022 Comparator	Jan 2005 → Jun 2008	—	University of New Mexico	Completed	No outcome recorded
—	NCT01569945 Comparator	Sep 2004 → Dec 2010	infertility disorder	University Hospital, Gasthuisberg	Completed	No outcome recorded
—	NCT00554632 Comparator	Apr 2003 → Aug 2005	venous thromboembolism	University of Vermont	Completed	No outcome recorded
—	NCT00600106 Comparator	Dec 1999 → May 2003	myocardial ischemia	Cedars-Sinai Medical Center	Completed	No outcome recorded

Press releases naming this drug 4 releases

Date	Issuer	Release
2024-04-15	Organon and Co	Organon’s HADLIMA™ (adalimumab-bwwd) and NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) Added to Mark Cuban’s Cost Plus Drugs organon.com ↗
2021-01-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States tevapharm.com ↗
2017-03-16	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States tevapharm.com ↗
2013-03-29	Teva Branded Pharmaceutical Products R&D, Inc.	FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy tevapharm.com ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 399 sources stand behind the page.

Field	Value	Cited text
Known as	ethinyl estradiol	“The proposed study will use participants that currently use a specific preparation of oral contraceptive (30micrograms ethinyl estradiol and 150mg Levonorgestrel) and compare...” NCT06560944 ↗ 395 “Participants received a monophasic combined oral contraceptive pills containing 0.03 mg ethinyl estradiol and 3 mg drospirenone (Technospiron® 0.03/3 mg, Technopharm, Egypt),...” NCT07229209 ↗ “OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21...” NCT03236740 ↗ “combined oral contraceptive pill (OCP) once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), starting from the first day of menses, then...” NCT05594186 ↗ “The purpose of the proposed project is to address the potential mechanism(s) by which oral ethinyl estradiol (EE) may negatively impair bone via "first pass" effects on the...” NCT02367833 ↗ “The aim of this study was to investigate the bleeding pattern and cycle control of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453585 ↗ Oct 2014 “A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when...” NCT05505162 ↗ “An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of BMS-986322 at Steady State and Multiple Doses of a Combined Oral Hormonal...” NCT05579574 ↗ “Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10...” NCT01252186 ↗ “Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone...” NCT02710708 ↗ “OBJECTIVE(S): To investigate the bleeding pattern and cycle control parameters of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453582 ↗ Oct 2014 “Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one...” NCT01254292 ↗ “A study to evaluate pharmacokinetic profile, wearability and safety of AG200-15, transdermal delivery of levonorgestrel (LNG) and ethinyl estradiol (EE), under normal...” NCT01375946 ↗ “Multicenter, Open-label, Uncontrolled Study to Investigate Suppression of Ovarian Activity of a Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg...” NCT02550977 ↗ “Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days...” NCT02089620 ↗ “A Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval Compared to...” NCT00196365 ↗ “Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28...” NCT00511342 ↗ “The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE,...” NCT07074327 ↗ “Ethinylestradiol (EE)-based combined oral contraceptives (COC) affect adrenal function by altering steroid and corticosteroid-binding globulin (CBG) synthesis that may...” PMID 36084710 ↗ Sep 2022 “This study is being conducted to evaluate the safety of an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for...” NCT00196352 ↗ “randomly assigned to receive either oral contraceptives (triphasic ethinyl estradiol at a dose of 35 microg plus norethindrone at a dose of 0.5 to 1 mg for 12 cycles of 28 days...” PMID 16354891 ↗ Dec 2005 “OBJECTIVE: To investigate the effects of low-dose ethinyl estradiol (EE) on the clinical pregnancy rate among women with polycystic ovary syndrome (PCOS) undergoing ovulation...” PMID 26391671 ↗ Sep 2015 “a monophasic oral contraceptive's active components, ethinyl estradiol (EE) and norethindrone acetate (NET), following a single oral dose alone and in combination with IW-3718...” NCT03856970 ↗ “The used preparations are: Vaginal ring, depotproduct: ethinylestradiol 2.7 mg (0,015 mg/day) and etonogestrel 11.7 mg (0,120 mg/day)and the contraceptive pill,...” NCT01588873 ↗ “Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once...” NCT07127458 ↗ “The objective of these study was to evaluate the effect of the use of a contraceptive containing 20 mcg of ethinyl estradiol and 3mg of drospirenone in the autonomic nervous...” NCT01590849 ↗ “Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal...” NCT00394771 ↗ “Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day...” NCT00413062 ↗ “An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy...” NCT02159131 ↗ “Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg) daily for 21 days starting from the 3rd day of menstruation in addition to oral...” NCT02562053 ↗ “To evaluate long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone and DRSP/EE plus metformin on some cardiovascular risk factors in...” NCT01581814 ↗ “1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium...” NCT01360996 ↗ “On Day 1 and Day 14, participants will orally take one tablet of Drospirenone and Ethinylestradiol Tablets (containing Drospirenone 3 mg and Ethinylestradiol 0.03 mg) under...” NCT07181343 ↗ “ORTHO EVRA is a combination transdermal (through the skin) contraceptive patch containing 6.00 mg of the progestin norelgestromin (NGMN) and 0.75 mg of the estrogen, ethinyl...” NCT01535820 ↗ “0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free...” NCT01204190 ↗ “A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy...” NCT01953809 ↗ “An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17dNorgestimate and Ethinyl Estradiol With the Oral Contraceptive Mercilon.” NCT00236782 ↗ “A Phase 1 Study to Characterize the Effects of BMS-986166 on the Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Female Participants” NCT04934696 ↗ “Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)” NCT00310791 ↗ “Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.” PMID 21679006 ↗ 2011 “Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months” NCT02342093 ↗ “this study set out to compare the cycle control and bleeding profile of drospirenone (DRSP) 3 mg/ethinylestradiol (EE) 20 μg in a 24-active pill/4-inert pill (24/4) regimen (YAZ®)” PMID 21721590 ↗ 2011 “Investigation of the Effect of NNC0174-0833 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Females of Non-childbearing Potential” NCT04074174 ↗ “A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo” NCT00196313 ↗ “Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation” NCT02488538 ↗ “A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene” NCT00933179 ↗ “Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.” PMID 21288628 ↗ Feb 2011 “Participants were given the recommended dietary allowance of Vit D (600 IU daily) plus hormonal contraception (HC; cyclic ethinyl estradiol/drospirenone) or no HC for 6 months.” PMID 38303661 ↗ Feb 2024 “Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles” NCT00185484 ↗ “Healthy women (18-45 years) received an ethinylestradiol (EE) 20 mcg/drospirenone 3 mg OC in two flexible extended regimens or in a conventional 24/4 (i.e., 28-day) regimen.” PMID 22281416 ↗ Jan 2012 “In Period 1, patients received one Microgynon tablet (ethinylestradiol 30 μg and levonorgestrel 150 μg) ≥ 3 days before the first administration of nintedanib in Period 2.” PMID 34664183 ↗ Oct 2021 “A ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 0·15 mg segesterone acetate and 0·013 mg ethinylestradiol per day.” PMID 31231065 ↗ Jun 2019 “Participants will receive a single dose of Portia (30 mcg of ethinyl estradiol (EE) and 150 mcg of levonorgestrel (LN)) or equivalent oral tablet in the morning on Day 1” NCT07190430 ↗ “A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424 (Dienogest 2 mg / Ethinyl Estradiol 0.02 mg) During 13 Cycles” NCT03945513 ↗ “1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles” NCT00280657 ↗ “A Study to Evaluate the Effect of a Contraceptive Vaginal Ring LSP- 5415 Releasing Ethinyl Estradiol Plus Etonogestrel on Ovarian Function in Healthy Adult Females” NCT05360550 ↗ “Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial.” PMID 28911925 ↗ Sep 2017 “Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle.” NCT01475513 ↗ “An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155” NCT01077505 ↗ “0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.” NCT01638767 ↗ “STUDY DESIGN: Thirty-three women were randomly assigned 1:1 to one of two OCs with 35-mcg ethinylestradiol (EE2) but different doses of NET - 1 or 0.4 mg.” PMID 22325110 ↗ Feb 2012 “combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)” NCT01963403 ↗ “COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.” NCT00483535 ↗ “Subjects participating in the study will be treated with an oral contraceptive pill containing 0.03 mg ethinylestradiol and 0.125 mg levonorgestrel.” NCT00220324 ↗ “The investigational product is an oral contraceptive that contains the estrogen ethinylestradiol and the progestin dienogest as active ingredients.” NCT00471991 ↗ “one with an androgenic progestin (ethinyl estradiol [EE]/levonorgestrel [LNG]) on sexual function in women with COC-associated sexual dysfunction.” PMID 24034466 ↗ Sep 2013 “tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.” NCT02237131 ↗ “Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study.” NCT03905941 ↗ “Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception” NCT01902264 ↗ “First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)” NCT02669238 ↗ “co-formulated Tenofovir Disoproxil Fumarate and Emtricitabine (FTC/TDF) plus combined ethinyl estradiol/levonorgestrel oral contraceptive (COC)” NCT07288190 ↗ “Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28” NCT00511433 ↗ “one group received oral contraceptive pills and the other one received cyproterone acetate combined ethinyl-estradiol(Diane) for 3 months.” NCT00955058 ↗ “An oral contraceptive Altavera \[levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg\] will be administered orally.” NCT07525791 ↗ “COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.” NCT00508911 ↗ “20 mcg ethinyl estradiol (EE)/100 mcg levonorgestrel (LNG) dosed cyclically (21 days active pills with 7-day placebo week) for two cycles” PMID 25070547 ↗ Jun 2014 “14 pills of study drug (150 microgram levonorgestrel and 30 microgram ethinyl estradiol combined OCPs) or an identical-appearing placebo” PMID 26181091 ↗ Sep 2015 “AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)” NCT02158572 ↗ “A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider.” NCT02002260 ↗ “A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.” NCT04255277 ↗ “treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles” NCT00517556 ↗ “Ethinylestradiol (35 µg) and norethindrone (1.0 mg) are the components of Ovysmen, which is a widely used oral contraceptive (OC).” NCT01486004 ↗ “an oral contraceptive (OC) containing norethindrone (NE) and ethinyl estradiol (EE) (ORTHO-NOVUM® tablets: 1 mg NE + 0.035 mg EE)” NCT02292732 ↗ “a monophasic combination OC containing 1 mg norethindrone and 35 mug of ethinyl estradiol, each administered three times per day” PMID 17012455 ↗ Oct 2006 “The investigational drug used in this study contains the estrogen ethinylestradiol (EE) and the progestogen drospirenone (DRSP).” NCT00569244 ↗ “Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.” NCT02170038 ↗ “subcutaneous IFN-β-1a 44 mcg tiw plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (Mercilon®, MSD Italia SRL, Rome, Italy)” PMID 27995531 ↗ Feb 2017 “oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans.” NCT07361263 ↗ “Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects” NCT02832180 ↗ “0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin)” NCT00185354 ↗ “active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD)” NCT04172987 ↗ “Kurvelo®: 30mcg ethinyl estradiol (EE) and 0.15mg levonorgestrel (LNG), a synthetic estrogen and progestin, respectively.” NCT07544966 ↗ “NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition” NCT01246791 ↗ “Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study.” NCT00029159 ↗ “Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily” NCT02689843 ↗ “Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.” NCT03954366 ↗ “monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily” NCT02922348 ↗ “The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.” NCT03843736 ↗ “One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.” NCT01714193 ↗ “One packet consists of 21 active pills, containing 150 micrograms levonorgestrel and 30 microgram ethinylestradiol.” NCT05212389 ↗ “subjects were randomized to receive either 1 mg norethindrone/10 microg ethinyl estradiol or placebo for 12 weeks.” PMID 20569710 ↗ Jun 2010 “Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects” NCT03506399 ↗ “one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)” NCT03357640 ↗ “combined oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-childbearing Potential.” NCT06657105 ↗ “Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.” NCT03984825 ↗ “patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)” NCT02599077 ↗ “Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.” NCT00902746 ↗ “Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg.” NCT01757249 ↗ “(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.” NCT01310647 ↗ “42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;” NCT00996580 ↗ “Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone” NCT00567164 ↗ “Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily” NCT06083935 ↗ “quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene” NCT03077555 ↗ “Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.” NCT00827632 ↗ “Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch.” NCT00439972 ↗ “The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen).” NCT01813162 ↗ “1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo” NCT01465022 ↗ “Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.” NCT01044498 ↗ “Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo” NCT00778609 ↗ “20 µg ethinyl estradiol/75 µg gestodene (EE/GS), starting treatment between cycle day 7 and 9.” PMID 41388035 ↗ Dec 2025 “INTERVENTION(S): Ethinyl estradiol (35 μg) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles.” PMID 21676394 ↗ Jun 2011 “Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days” NCT00826839 ↗ “Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.” NCT00647933 ↗ “exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream” NCT00258076 ↗ “EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day” NCT05994599 ↗ “During Cycle 2 and 3 the PK of ethinyl estradiol (EE) and active metabolites of norgestimate” NCT02792517 ↗ “Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)” NCT02215395 ↗ “single dose kinetics of a combination of ethinylestradiol and levonorgestrel (Microgynon®)” NCT02751385 ↗ “0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.” NCT00764881 ↗ “low-dose levonorgestrel (LNG) and ethinyl estradiol (EE) contraceptive patch (CP, Twirla™)” PMID 25582984 ↗ Nov 2014 “30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles” NCT00367276 ↗ “Yasmin, drospirenone and ethinyl estradiol 28 tablets 1 tab daily for duration of study” NCT00283816 ↗ “oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks” NCT02257671 ↗ “Ethinyl estradiol (EE) and the progestin gestodene are well-absorbed through the skin” PMID 24043457 ↗ Sep 2013 “LNG/ethinyl estradiol (EE)/ferrous fumarate combined oral contraceptive (COC) regimen” NCT05233956 ↗ “Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.” NCT00924560 ↗ “oral contraceptive YASMIN (containing: drospirenone 3 mg/ethinyl estradiol 30 mcg)” NCT00651846 ↗ “the effects of ethinyl estradiol on bone calcium balance using the 41Ca technology” NCT02367846 ↗ “35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally” NCT01373931 ↗ “a generic oral contraceptive with 30ug ethinyl estradiol and 0.15mg levonorgestrel” NCT00229996 ↗ “1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days” NCT00461305 ↗ “20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP)” NCT00266032 ↗ “One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day” NCT01892904 ↗ “0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin” NCT01258660 ↗ “ethinylestradiol (EE) and levonorgestrel (LNG), the components of Microgynon®” NCT02175394 ↗ “Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)” NCT00927095 ↗ “Brand name :FLAME containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene.” NCT03230825 ↗ “COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)” NCT03478020 ↗ “activity that is available in combination with ethinyl estradiol (EE) as a” PMID 40164172 ↗ Mar 2025 “Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen.” NCT00754065 ↗ “Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring)” NCT04423068 ↗ “30 mcg ethinyl estradiol and LNG 150 combination oral contraceptive pills” NCT01388582 ↗ “MR-100A-01 is a TDS of norelgestromin 4.86 mg/ethinyl estradiol 0.264 mg.” NCT05139121 ↗ “One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.” NCT01324505 ↗ “Levora® (ethinyl estradiol 0.3 mg (EE) and levonorgestrel 0.15 mg (LNG)” NCT02641990 ↗ “Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a weak CYP3A4 inhibitor” NCT02080468 ↗ “Drospirenone 1 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)” NCT00511797 ↗ “COCs containing drospirenone and ethinylestradiol (EE) versus placebo” PMID 37365881 ↗ Jun 2023 “0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone” NCT01257984 ↗ “0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone” NCT02617537 ↗ “0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles” NCT00873483 ↗ “Oral Contraceptive (ethinylestradiol [EE] and levonorgestrel [LN])” NCT07710729 ↗ “0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in a 21-day Regimen” NCT00910637 ↗ “contraceptive vaginal ring with ethinyl estradiol and etonogestrel” NCT02529683 ↗ “30 mcg of ethinyl estradiol [EE], 150 mcg of levonorgestrel [LNG]” NCT04778514 ↗ “a contraceptive (levonorgestrel (LNG) and ethinyl estradiol [EE])” NCT06793943 ↗ “0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks” NCT04256200 ↗ “COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7” NCT04451746 ↗ “ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks” NCT01414530 ↗ “ethinyl estradiol (EE), an estrogen used in oral contraceptives” NCT00263341 ↗ “a synthetic form oestrogen (ethinyl estradiol) given as a patch” NCT07010146 ↗ “20 mcg ethinylestradiol combined with 3 mg drospirenone (Yaz)” NCT03091595 ↗ “Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets” NCT03037944 ↗ “20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd” NCT00824187 ↗ “30 mcg Ethinylestradiol (EE) and 150 mcg Levonorgestrel (LNG)” NCT02957630 ↗ “Part B: Ethinyl Estradiol/ Levonorgestrel (EE/LNG) + AZD5004” NCT06942936 ↗ “low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol)” PMID 41359669 ↗ Dec 2025 “20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd” NCT00819312 ↗ “20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd” NCT00818519 ↗ “30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.” NCT00948402 ↗ “ethinyl estradiol and levonorgesterol oral contraceptives” NCT00918476 ↗ “3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)” NCT00511199 ↗ “Part A: SUZ with Drospirenone/Ethinyl Estradiol (DRSP/EE)” NCT06820307 ↗ “containing levonorgestrel and ethinylestradiol (LNG/EE).” PMID 22066891 ↗ Dec 2011 “ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG)” PMID 19835717 ↗ May 2009 “NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol)” NCT01253824 ↗ “20 micrograms ethinyl estradiol and desogestrel 0.15mg” NCT06852365 ↗ “Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)” NCT01076582 ↗ “drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE)” NCT00656981 ↗ “20 microgram ethinyl estradiol and 150 mg desogestrel” NCT01482338 ↗ “ethinylestradiol (EE) 20 μg/drospirenone (DRSP) 3 mg” PMID 22454004 ↗ Apr 2012 “Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone” NCT04831151 ↗ “drospirenone (DRSP) 3 mg/ethinylestradiol (EE) 20 μg” PMID 21721590 ↗ 2011 “Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg” NCT04539626 ↗ “containing levonorgestrel/ethinylestradiol (LNG/EE)” PMID 22762147 ↗ Aug 2012 “norelgestromin [NGMN] and ethinyl estradiol [EE]” NCT04017195 ↗ “ethinyl estradiol 0.035mg and norethisterone 1mg” NCT00746096 ↗ “1.5 mg Norethindrone and 30ug ethinyl estradiol” NCT04016753 ↗ “0.25 mg norgestimate/0.035 mg ethinyl estradiol” NCT02494609 ↗ “Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg” NCT02362711 ↗ “ethinylestradiol (EE) and levonorgestrel (LNG)” NCT05613777 ↗ “Ethinylestradiol (EE) and Levonorgestrel (LNG)” NCT05896384 ↗ “ethinyl estradiol [EE] and norgestimate [NGM])” NCT03783897 ↗ “Ethinylestradiol (EE) and Drospirenone (DRSP)” NCT05934942 ↗ “Metformin, Ethinylestradiol 30µg-Drospirenone” NCT01459445 ↗ “Ethinyl estradiol / dienogest (SH D00659 AF)” NCT00471991 ↗ “Norethisterone 1mg, Ethinyl estradiol 0.02mg” NCT01129102 ↗ “0.03 mg Ethinylestradiol and 2 mg Dienogest” NCT00302666 ↗ “drospirenone (DRSP)/ethinyl estradiol (EE)” NCT07235774 ↗ “ethinyl estradiol (EE)/norethindrone (NET)” NCT02182791 ↗ “ethinylestradiol/levonorgestrel (EE/LNG).” PMID 21721593 ↗ 2011 “Ethinylestradiol (EE) and Gestodene (GSD)” NCT01083264 ↗ “30 µg ethinylestradiol, 3mg drospirenone” NCT00185419 ↗ “Levonorgestrel-Ethinyl Estradiol COC” NCT02616146 ↗ NCT00932321 ↗ NCT07269327 ↗ NCT07714616 ↗ NCT07536763 ↗ NCT01709318 ↗ NCT03126097 ↗ NCT07502417 ↗ NCT06188026 ↗ NCT01941134 ↗ NCT03301207 ↗ NCT00254865 ↗ NCT03172533 ↗ NCT06334315 ↗ NCT02885454 ↗ NCT00254800 ↗ NCT02400801 ↗ NCT00245921 ↗ NCT00319163 ↗ NCT04230070 ↗ NCT00662454 ↗ NCT00915915 ↗ NCT01466673 ↗ NCT00204451 ↗ NCT02652650 ↗ NCT00999479 ↗ NCT00204438 ↗ NCT00248963 ↗ NCT00033358 ↗ NCT07013643 ↗ NCT00236769 ↗ NCT03608241 ↗ NCT00873483 ↗ NCT00391807 ↗ NCT00344383 ↗ NCT03074045 ↗ NCT03755037 ↗ NCT01328184 ↗ NCT07272889 ↗ NCT06513104 ↗ NCT00946192 ↗ NCT04309643 ↗ NCT07523711 ↗ NCT07414784 ↗ NCT01087879 ↗ NCT03890341 ↗ NCT00653016 ↗ NCT06380205 ↗ NCT03890042 ↗ NCT02352090 ↗ NCT03881904 ↗ NCT00732693 ↗ NCT00161681 ↗ NCT02460445 ↗ NCT02556411 ↗ NCT04142762 ↗ NCT00301587 ↗ NCT01511822 ↗ NCT00709982 ↗ NCT07340190 ↗ NCT01573377 ↗ NCT01519401 ↗ NCT04018274 ↗ NCT03043924 ↗ NCT02103569 ↗ NCT04972396 ↗ NCT03557619 ↗ NCT07539090 ↗ NCT01174524 ↗ NCT03124524 ↗ NCT02757469 ↗ NCT03249402 ↗ NCT00554632 ↗ NCT02021097 ↗ NCT03662516 ↗ NCT00829114 ↗ NCT06250205 ↗ NCT01056042 ↗ NCT00089414 ↗ NCT07083635 ↗ NCT01344369 ↗ NCT06799884 ↗ NCT01448291 ↗ NCT00193726 ↗ NCT04828824 ↗ NCT00442689 ↗ NCT00261482 ↗ NCT02846142 ↗ NCT07513480 ↗ NCT01608698 ↗ NCT06461039 ↗ NCT02531321 ↗ NCT00909857 ↗ NCT00307632 ↗ NCT00729404 ↗ NCT05064332 ↗ NCT00612508 ↗ NCT03709355 ↗ NCT02866786 ↗ NCT01388491 ↗ NCT06396208 ↗ NCT05706753 ↗ NCT03531437 ↗ NCT00338052 ↗ NCT07215806 ↗ NCT00237042 ↗ NCT04278755 ↗ NCT01570244 ↗ NCT01490190 ↗ NCT00128934 ↗ NCT06396221 ↗ NCT01291004 ↗ NCT01569945 ↗ NCT04267250 ↗ NCT00914693 ↗ NCT03324685 ↗ NCT05985590 ↗ NCT00821496 ↗ NCT00984789 ↗ NCT00896571 ↗ NCT00709332 ↗ NCT00633360 ↗ NCT00468481 ↗ NCT07568509 ↗ NCT03359057 ↗ NCT04194905 ↗ NCT04709094 ↗ NCT00640224 ↗ NCT00320567 ↗ NCT01501448 ↗ NCT00254189 ↗ NCT00006133 ↗ NCT03111511 ↗ NCT02036879 ↗ NCT01569113 ↗ NCT06316206 ↗ NCT00191113 ↗ NCT04290390 ↗ NCT00357604 ↗ NCT05282940 ↗ NCT00455156 ↗ NCT00117260 ↗ NCT00722761 ↗ NCT02705963 ↗ NCT05002738 ↗ NCT07242131 ↗ NCT06039826 ↗ NCT00722800 ↗ NCT06671405 ↗ NCT00570440 ↗ NCT02210702 ↗ NCT01103518 ↗ NCT03353857 ↗ NCT02144246 ↗ NCT01250210 ↗ NCT00212277 ↗ NCT00212342 ↗ NCT00511355 ↗ NCT01040845 ↗ NCT01546454 ↗ NCT06324851 ↗ NCT01044056 ↗ NCT03262740 ↗ NCT04193852 ↗ NCT06233058 ↗ NCT06233071 ↗ NCT00258063 ↗ NCT04272008 ↗ NCT01597986 ↗ NCT04713904 ↗ NCT02027337 ↗ NCT00195559 ↗ NCT00236782 ↗ NCT03106454 ↗ NCT07388511 ↗ NCT05093205 ↗ NCT02577601 ↗ NCT00236795 ↗ NCT01508858 ↗ NCT00213096 ↗ NCT01656434 ↗ NCT02729545 ↗ NCT04007874 ↗
Known as	28-day Levonorgestrel Oral Contraceptive	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01252186 ↗
Known as	EE	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03091595 ↗
Known as	EE2	“STUDY DESIGN: Thirty-three women were randomly assigned 1:1 to one of two OCs with 35-mcg ethinylestradiol (EE2) but different doses of NET - 1 or 0.4 mg.” PMID 22325110 ↗ Feb 2012
Known as	EE20	“20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP)” NCT00266032 ↗ 1 “Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)” NCT02710708 ↗
Known as	ethinyloestradiol	“The volunteers received an oral single-dose of a combined contraceptive containing 30 μg ethinyloestradiol and 150 μg levonorgestrel on two occasions - once as such and once...” NCT02281448 ↗ 5 “An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple...” NCT06942936 ↗ “with a monophasic COC containing ethinyloestradiol/levonorgestrel (EE/LNG), with regard to their ability to reduce the frequency and intensity of headache and pelvic pain” PMID 23919857 ↗ Aug 2013 “7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules” NCT01384331 ↗ “ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles” NCT01372293 ↗ NCT01137708 ↗
Known as	Minidril	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01297179 ↗
Known as	Norelgesetromin	“Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg” NCT04539626 ↗
Action	Inhibit	“Inhibition of Ovulation” NCT00915915 ↗
Modality	Small molecule	“14-day course of combined oral hormonal steroids” NCT01968135 ↗
Route	Oral	“oral contraceptives (triphasic ethinyl estradiol at a dose of 35 microg” PMID 16354891 ↗ Dec 2005